NBIX NEUROCRINE BIOSCIENCES INC revenue, earnings and financials

For the quarter ended June 30, 2026, NEUROCRINE BIOSCIENCES INC reported revenue of $959M (up 39.5% from a year earlier), net income of $144M and diluted EPS of $1.39; over the last four quarters revenue was $3.37B and net income $706M; for the fiscal year ended December 2025 revenue was $2.86B, up 21.4% on the year before.

NBIX annual revenue and earnings

• Fiscal year ended Dec 2025: revenue $2.86B, gross profit n/a, operating income $619M, net income $479M (margin 16.7%), EPS $4.67
• Fiscal year ended Dec 2024: revenue $2.36B, gross profit n/a, operating income $571M, net income $341M (margin 14.5%), EPS $3.29
• Fiscal year ended Dec 2023: revenue $1.89B, gross profit n/a, operating income $251M, net income $250M (margin 13.2%), EPS $2.47
• Fiscal year ended Dec 2022: revenue $1.49B, gross profit n/a, operating income $249M, net income $155M (margin 10.4%), EPS $1.56
• Fiscal year ended Dec 2021: revenue $1.13B, gross profit n/a, operating income $103M, net income $89.6M (margin 7.9%), EPS $0.92

NBIX quarterly revenue and earnings

• Quarter ended Jun 30, 2026: revenue $959M (up 39.5% year over year), net income $144M, EPS $1.39
• Quarter ended Mar 31, 2026: revenue $815M (up 42.2% year over year), net income $198M, EPS $1.91
• Quarter ended Dec 31, 2025 (from the annual report): revenue $806M (up 28.3% year over year), net income $154M, EPS $1.49
• Quarter ended Sep 30, 2025: revenue $795M (up 27.8% year over year), net income $210M, EPS $2.04
• Quarter ended Jun 30, 2025: revenue $688M (up 16.5% year over year), net income $108M, EPS $1.06
• Quarter ended Mar 31, 2025: revenue $573M (up 11.1% year over year), net income $7.90M, EPS $0.08
• Quarter ended Dec 31, 2024 (from the annual report): revenue $628M (up 21.8% year over year), net income $103M, EPS $1.00
• Quarter ended Sep 30, 2024: revenue $622M (up 24.7% year over year), net income $130M, EPS $1.24
• Quarter ended Jun 30, 2024: revenue $590M (up 30.4% year over year), net income $65.0M, EPS $0.63
• Quarter ended Mar 31, 2024: revenue $515M (up 22.6% year over year), net income $43.4M, EPS $0.42
• Quarter ended Dec 31, 2023 (from the annual report): revenue $515M (up 25.0% year over year), net income $148M, EPS $1.49
• Quarter ended Sep 30, 2023: revenue $499M (up 28.6% year over year), net income $83.1M, EPS $0.82
• Quarter ended Jun 30, 2023: revenue $453M (up 19.7% year over year), net income $95.5M, EPS $0.95
• Quarter ended Mar 31, 2023: revenue $420M (up 35.4% year over year), net income −$76.6M, EPS −$0.79
• Quarter ended Dec 31, 2022 (from the annual report): revenue $412M (up 32.1% year over year), net income $89.0M, EPS $0.91
• Quarter ended Sep 30, 2022: revenue $388M (up 31.0% year over year), net income $68.5M, EPS $0.69
• Quarter ended Jun 30, 2022: revenue $378M (up 30.9% year over year), net income −$16.9M, EPS −$0.18
• Quarter ended Mar 31, 2022: revenue $311M (up 31.3% year over year), net income $13.9M, EPS $0.14
• Quarter ended Dec 31, 2021 (from the annual report): revenue $312M, net income −$7.30M, EPS −$0.07
• Quarter ended Sep 30, 2021: revenue $296M, net income $22.5M, EPS $0.23

NBIX cash flow, buybacks and dividends

• Fiscal year ended Dec 2025: operating cash flow $783M, share buybacks $168M
• Fiscal year ended Dec 2024: operating cash flow $595M, share buybacks $300M
• Fiscal year ended Dec 2023: operating cash flow $390M, share buybacks $0
• Fiscal year ended Dec 2022: operating cash flow $339M, share buybacks $0
• Fiscal year ended Dec 2021: operating cash flow $257M, share buybacks n/a

NBIX balance sheet

• Jun 30, 2026: cash $332M, total assets $5.36B, total liabilities $1.67B, shareholders' equity $3.69B
• Mar 31, 2026: cash $267M, total assets $4.91B, total liabilities $1.50B, shareholders' equity $3.41B
• Dec 31, 2025: cash $713M, total assets $4.63B, total liabilities $1.38B, shareholders' equity $3.25B
• Sep 30, 2025: cash $340M, total assets $4.27B, total liabilities $1.26B, shareholders' equity $3.00B
• Jun 30, 2025: cash $264M, total assets $3.89B, total liabilities $1.20B, shareholders' equity $2.69B
• Mar 31, 2025: cash $194M, total assets $3.69B, total liabilities $1.15B, shareholders' equity $2.54B
• Dec 31, 2024: cash $233M, total assets $3.72B, total liabilities $1.13B, shareholders' equity $2.59B
• Sep 30, 2024: cash $349M, total assets $3.54B, total liabilities $816M, shareholders' equity $2.72B

What is NBIX's revenue?

NEUROCRINE BIOSCIENCES INC reported $3.37B of revenue over its last four quarters, through June 30, 2026.

Is NBIX profitable?

Yes. NEUROCRINE BIOSCIENCES INC earned $706M over the last four quarters.

What is NBIX's EPS?

Diluted earnings per share over the last four quarters were $6.83; $1.39 in the latest quarter.

NBIX ownership and insider trades · All stocks